Summit Day One Agenda
7:00 am Registration
7:55 am Chairs Opening Remarks
The Market Perspective
8:00 am Panel Discussion: Exploring the Dermatology Financing Landscape for 2022 & Beyond
Synopsis
- What are large pharma looking for when partnering & how can smaller biotechs best prepare to partner
- How & where do you begin with developing a candidate for the rare disease space
- Debating how to position your drug candidate in the market where patients have failed other trials
8:30 am Development of a Topical Drug Product in the post-pandemic world
9:00 am Growing Our Patient-Focused Dedication to Alopecia Areata
Synopsis
- Reviewing the journey to delivering the world’s first FDA-approved oral JAK inhibitor to demonstrate hair regrowth in Alopecia Areata patients
9:30 am Highlighting Opportunities for Novel Drug Development in Hidradenitis Suppurativa
Synopsis
- Categorizing the disease and providing the context around unmet needs
- Outlining novel targets and cataloging the promising novel drug candidates for the disease
- Discussing the need for procedural intervention
10:00 am The Beautiful Collagens of the Skin – Understanding the Extracellular Matrix to Aid Personalized Medicine and Drug Development
Synopsis
- Different collagens mean very different things
- The importance of understanding the tissue turnover profiles in Atopic Dermatitis, Hidradenitis Suppurativa and Scleroderma as examples
- Quantifying collagen age and crosslinks to understand skin health
10:30 am Morning Break & Structured Networking Session
Novel Drug Development & Various Promising Pathways
Track A: IL-4, IL-13 & IL-31 Associated Diseases
Jennifer Gaskin, Senior Director Clinical Operations, Celldex Therapeutics
11:30 am A Novel Approach to Treating Pruritus in Prurigo Nodularis
Synopsis
- Rationalizing the dual mechanism of action approach as both an antagonist (mu opioid receptor) & agonist (kappa opioid receptor)
- Providing fresh efficacy data from a phase 3 clinical trial
- Addressing the challenges with entering the prurigo nodularis market
12:00 pm Spearheading a Novel Compound Targeting the IL-4Ra Cytokine Receptor in Atopic Dermatitis
Synopsis
- Describing the target binding and Th2 cell modulation
- Clinical responses from a phase 2b clinical trial in atopic dermatitis
- Future clinical development
12:30 pm Human & Machine: Optimising dermatology clinical trials by AI assisted disease monitoring and quantitative assessment of skin drug effects
Synopsis
- Standardized high quality skin imaging
- Smart skin imaging data and image analysis
- Machine learning and decision support in trials
- Patient reported outcome and real world evidence
Track B: IL17 Associated Diseases, Alopecia & Vitiligo
John Reader, Chief Scientific Officer, Sareum
11:30 am Spearheading a Novel Drug Candidate in Chronic Inflammatory Skin and Joint Diseases
Synopsis
- Outlining the emerging story of IL-17A and F in inflammatory diseases
- How to Optimize targeting an important cytokine pathway – MOA and unique molecule characteristics of the novel IL-17 drug candidate sonelokimab
- Showcasing disease control by sonelokimab from a phase 2b trial in psoriasis
- Broadening the spectrum – Preparing for success in HS and PsA
12:00 pm How to Approach Vitiligo: A Holistic Overview of the Vitiligo Drug Development Space
Synopsis
- Benchmarking the most promising novel drug candidates in development for the treatment of Vitiligo
- Incorporating the perspective from the clinic to enhance drug development
- Exploring the need for increased DEI in the context of Vitiligo